ESR1 and breast cancer: Theoretically, providing docetaxel for metastatic estrogen receptor-positive breast cancer when the ovary is in the follicular phase of the menstrual cycle [36] when estradiol approaches peak levels, likely at 10–14 days from the beginning of the menstrual cycle, could be more potent than providing it during other parts of the cycle.